ATE472733T1 - Verfahren zur beurteilung von zellulären proliferativen erkrankungen - Google Patents

Verfahren zur beurteilung von zellulären proliferativen erkrankungen

Info

Publication number
ATE472733T1
ATE472733T1 AT01980092T AT01980092T ATE472733T1 AT E472733 T1 ATE472733 T1 AT E472733T1 AT 01980092 T AT01980092 T AT 01980092T AT 01980092 T AT01980092 T AT 01980092T AT E472733 T1 ATE472733 T1 AT E472733T1
Authority
AT
Austria
Prior art keywords
proliferative diseases
cellular proliferative
assessing cellular
assessing
diseases
Prior art date
Application number
AT01980092T
Other languages
English (en)
Inventor
Matthew Coffey
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Application granted granted Critical
Publication of ATE472733T1 publication Critical patent/ATE472733T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
    • G01N2333/135—Respiratory syncytial virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/14—Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
AT01980092T 2000-11-09 2001-10-26 Verfahren zur beurteilung von zellulären proliferativen erkrankungen ATE472733T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24672800P 2000-11-09 2000-11-09
PCT/CA2001/001512 WO2002039117A1 (en) 2000-11-09 2001-10-26 Methods for the treatment of cellular proliferative disorders

Publications (1)

Publication Number Publication Date
ATE472733T1 true ATE472733T1 (de) 2010-07-15

Family

ID=22931950

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01980092T ATE472733T1 (de) 2000-11-09 2001-10-26 Verfahren zur beurteilung von zellulären proliferativen erkrankungen

Country Status (17)

Country Link
US (3) US7052832B2 (de)
EP (2) EP1332366B1 (de)
JP (2) JP4146725B2 (de)
AR (1) AR031281A1 (de)
AT (1) ATE472733T1 (de)
AU (2) AU1202202A (de)
BR (1) BR0115235A (de)
CA (1) CA2428206C (de)
DE (1) DE60142485D1 (de)
DK (2) DK1332366T3 (de)
ES (2) ES2347523T3 (de)
HK (1) HK1142833A1 (de)
IL (1) IL154881A0 (de)
MX (1) MXPA03004029A (de)
NZ (1) NZ524937A (de)
WO (1) WO2002039117A1 (de)
ZA (1) ZA200302086B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
US20040115170A1 (en) * 2001-11-30 2004-06-17 Brown Earl Garnet Oncolytic virus
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
WO2007099401A2 (en) 2005-08-01 2007-09-07 University Technologies International, Inc. Oncolytic attenuated reoviruses for treatment of proliferative disorders
WO2007093036A1 (en) * 2006-02-13 2007-08-23 Oncolytics Biotech Inc. Use of local immune suppression to enhance oncolytic viral therapy
WO2008031230A1 (en) * 2006-09-15 2008-03-20 Dalhousie University Methods of determining susceptibility of cells to reovirus infection and methods for treating cellular proliferative disorders with reovirus
EP2132315B1 (de) 2007-03-12 2015-07-15 Oncolytics Biotech Inc. Reoviren mit modifizierten sequenzen
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
AR066649A1 (es) * 2007-05-21 2009-09-02 Oncolytics Biotech Inc Reovirus mutantes y metodos de elaboracion y uso de los mismos
JP2011500608A (ja) * 2007-10-22 2011-01-06 オンコリティクス バイオテク，インコーポレーテッド 増殖性障害の治療レジメン
TWI399369B (zh) 2008-04-02 2013-06-21 Nat Defense Medical Ct 咪唑蒽醌衍生物及其合成方法
TW200950777A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
CA2689707A1 (en) 2009-11-16 2011-05-16 Jean-Simon Diallo Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening
US20180305345A1 (en) 2015-01-26 2018-10-25 Ottawa Hospital Research Institute Compositions and methods for enhancing oncolytic virus efficacy
PT3518948T (pt) 2016-10-03 2023-07-17 Ottawa Hospital Res Inst Composições e métodos para melhorar o crescimento, a propagração e a eficácia imunoterapêutica de oncolítica de vírus de rna oncolíticos
CA2971832A1 (en) * 2017-06-23 2018-12-23 Roy Duncan Recombinant oncolytic viruses for treatment of metastatic cancers
SG11202003842UA (en) 2017-11-24 2020-06-29 Ottawa Hospital Res Inst Compositions and methods for enhancing production, growth, spread, or oncolytic and immunotherapeutic efficacy of interferon-sensitive viruses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia

Also Published As

Publication number Publication date
EP2189162B1 (de) 2013-11-27
ES2445704T3 (es) 2014-03-04
DK1332366T3 (da) 2010-08-02
US7763252B2 (en) 2010-07-27
NZ524937A (en) 2004-10-29
EP1332366B1 (de) 2010-06-30
US7052832B2 (en) 2006-05-30
ZA200302086B (en) 2004-03-15
CA2428206C (en) 2005-09-27
DK2189162T3 (da) 2014-02-03
HK1142833A1 (en) 2010-12-17
JP2008268200A (ja) 2008-11-06
AU2002212022B2 (en) 2006-03-30
US20020086284A1 (en) 2002-07-04
CA2428206A1 (en) 2002-05-16
DE60142485D1 (de) 2010-08-12
AR031281A1 (es) 2003-09-17
US7815914B2 (en) 2010-10-19
IL154881A0 (en) 2003-10-31
JP2004512385A (ja) 2004-04-22
EP1332366A1 (de) 2003-08-06
MXPA03004029A (es) 2004-02-12
US20080057073A1 (en) 2008-03-06
AU1202202A (en) 2002-05-21
JP4146725B2 (ja) 2008-09-10
US20060172288A1 (en) 2006-08-03
ES2347523T3 (es) 2010-11-02
WO2002039117A1 (en) 2002-05-16
BR0115235A (pt) 2003-10-14
EP2189162A1 (de) 2010-05-26

Similar Documents

Publication Publication Date Title
ATE472733T1 (de) Verfahren zur beurteilung von zellulären proliferativen erkrankungen
DE60221699D1 (de) Verfahren zur färbung von formkörpern
DE60216389D1 (de) Verfahren zur zerstörungsfreien Prüfung
DE50013673D1 (de) Verfahren zur Sichtweitenbestimmung
DE60143690D1 (de) Verfahren zur unterstützung von leistungsregelung
DE60132243D1 (de) Verfahren zum indizieren von entitäten
DE60335733D1 (de) Verfahren zur solubilisierung von protein
DE60124884D1 (de) Verfahren zur verbesserung der fotomaskengeometrie
DE60138344D1 (de) Verfahren zur Mutagenese
DE60125906D1 (de) Verfahren zur Verbesserung von Leistung
DE50104426D1 (de) Verfahren zur vernetzung von polyacrylaten
ATE416619T1 (de) Verfahren zur dearomatisierung von molkeprotein
DE60307617D1 (de) Verfahren zur gewinnung von gold
DE50209427D1 (de) Verfahren zur Entfernungsmessung
ATE321832T1 (de) Verfahren zur aufbereitung von oliven
ATE377957T1 (de) Verfahren zur anpassung von aromamischungen
DE60131397D1 (de) Verfahren zur gewinnung von cetamin-enantiomeren.
DE60104578D1 (de) Verfahren zur Denaturierung von Allergenen
ATE453724T1 (de) Verfahren zur bestimmung von löslichem fibrin
ATE301626T1 (de) Verfahren zur disproportionierung von isopentan
DE50014461D1 (de) Verfahren zur Ansteuerung von Rückhaltemitteln
DE50001116D1 (de) Verfahren zur justage von parabolantennen
DE50201799D1 (de) Verfahren zur gewinnung von n-phosphonomethylglycin
DE50000567D1 (de) Verfahren zur gefechtsfeldsimulation
DE50014809D1 (de) Verfahren zur Füllstandsmessung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties